The necessity for tumor-selective delivery systems (such nanocarrier-loaded LDHA inhibitors) or dual-target medications (like simultaneous inhibition of LDHA and HDAC) is highlighted by the danger of systemic metabolic disruptions associated with current LDH/MCT-targeting therapies. Here, HDAC9 is linked to neoplasm.